Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares saw unusually-strong trading volume on Friday . Approximately 144,279 shares were traded during mid-day trading, a decline of 0% from the previous session’s volume of 144,843 shares.The stock last traded at $8.01 and had previously closed at $7.79.

A number of equities analysts recently weighed in on KPTI shares. HC Wainwright started coverage on Karyopharm Therapeutics in a research report on Thursday. They issued a “buy” rating and a $15.00 price target for the company. Canaccord Genuity set a $20.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 6th. Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Monday, June 27th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 21st. Finally, Jefferies Group lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price target for the company. in a research report on Wednesday, June 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and an average price target of $17.25.

The firm has a 50 day moving average price of $7.20 and a 200-day moving average price of $7.82. The stock’s market capitalization is $290.79 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. On average, analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.26) earnings per share for the current fiscal year.

In other news, major shareholder Ltd Chione sold 18,824 shares of the business’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC increased its position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned about 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent reporting period.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.